Literature DB >> 28712557

Age modulates the relationship between platelet-to-lymphocyte ratio and coronary artery disease.

Issada Trakarnwijitr1, Bobby Li2, Heath Adams3, Jamie Layland4, John Garlick3, Andrew Wilson5.   

Abstract

BACKGROUND: Thrombocytosis and inflammation are vital elements in the pathogenesis of atherosclerosis. The platelet-to-lymphocyte ratio (PLR) is a novel biomarker that combines these parameters and has been shown to be associated with cardiovascular disease (CVD). This study aimed to determine whether PLR correlates with coronary artery disease (CAD) in high-risk patients, and if the relationship is affected by age.
METHODS: Consecutive patients referred for coronary angiogram were evaluated (n=822). with 608 patients demonstrating CAD, compared to 214 patients with normal coronary arteries. Patients were stratified into premature CAD (age<55) and non-premature CAD (age≥55). High and low PLR groups were defined as admission PLR in the highest (≥146.7) and lower two tertiles (<146.7) respectively. Multivariate logistic regression was undertaken to adjust for traditional cardiovascular risk factors.
RESULTS: In univariate analysis, high PLR negatively correlated with premature CAD (OR 0.45, 95%CI 0.23-0.87, P=0.017), while its association with CAD in older patients did not reach statistical significance (OR 1.32, 95%CI 0.89-1.97, P=0.170). After adjustment for traditional risk factors, high PLR was significantly associated with increased CAD in older patients (OR 2.22, 95%CI 1.28-3.82, P=0.004) but decreased premature CAD (OR 0.31, 95%CI 0.11-0.87, P=0.026).
CONCLUSIONS: There is an age-related effect on the correlation between PLR and CAD. While high PLR was an independent marker of CAD in older high-risk patients, it was negatively correlated with premature CAD in younger patients. PLR is widely available and inexpensive, and could be used in highlighting patients at high risk for CAD.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Inflammation; Lymphocyte; Platelet; Platelet-to-lymphocyte ratio; Premature coronary artery disease; Thrombocytosis

Mesh:

Substances:

Year:  2017        PMID: 28712557     DOI: 10.1016/j.ijcard.2017.06.127

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Association of Dietary Inflammatory Potential with Blood Inflammation: The Prospective Markers on Mild Cognitive Impairment.

Authors:  Xuan Wang; Tiantian Li; Hongrui Li; Dajun Li; Xianyun Wang; Ai Zhao; Wannian Liang; Rong Xiao; Yuandi Xi
Journal:  Nutrients       Date:  2022-06-10       Impact factor: 6.706

2.  Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease.

Authors:  Yanhua Zhen; Zhihui Chang; Zhaoyu Liu; Jiahe Zheng
Journal:  BMC Cardiovasc Disord       Date:  2020-01-09       Impact factor: 2.298

3.  Prognostic Impact of Multiple Lymphocyte-Based Inflammatory Indices in Acute Coronary Syndrome Patients.

Authors:  Qiuxuan Li; Xiaoteng Ma; Qiaoyu Shao; Zhiqiang Yang; Yufei Wang; Fei Gao; Yujie Zhou; Lixia Yang; Zhijian Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-03

4.  The Association between Systemic Immune-Inflammation Index and All-Cause Mortality in Acute Ischemic Stroke Patients: Analysis from the MIMIC-IV Database.

Authors:  Shaosheng Wu; Xiaoting Shi; Quan Zhou; Xiangjie Duan; Xiongfei Zhang; Huajing Guo
Journal:  Emerg Med Int       Date:  2022-08-02       Impact factor: 1.621

5.  Prognostic role of platelet to lymphocyte ratio in esophageal cancer: A meta-analysis.

Authors:  Qing-Tao Zhao; Xiao-Peng Zhang; Hua Zhang; Guo-Chen Duan
Journal:  Oncotarget       Date:  2017-11-20

6.  Prognostic value of peripheral blood inflammatory cell subsets in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Xiuxin Gao; Yixiang Liu; Yanan Tian; Chongyou Rao; Fei Shi; Haiwei Bu; Jingyi Liu; Ying Zhang; Weichao Shan; Zhenjiang Ding; Lixian Sun
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.